GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Align Technology Inc (NAS:ALGN) » Definitions » ROE %

Align Technology (Align Technology) ROE %

: 13.35% (As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Align Technology's annualized net income for the quarter that ended in Dec. 2023 was $496 Mil. Align Technology's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $3,716 Mil. Therefore, Align Technology's annualized ROE % for the quarter that ended in Dec. 2023 was 13.35%.

The historical rank and industry rank for Align Technology's ROE % or its related term are showing as below:

ALGN' s ROE % Range Over the Past 10 Years
Min: 10.01   Med: 21.28   Max: 77.55
Current: 12.26

During the past 13 years, Align Technology's highest ROE % was 77.55%. The lowest was 10.01%. And the median was 21.28%.

ALGN's ROE % is ranked better than
81.8% of 813 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs ALGN: 12.26

Align Technology ROE % Historical Data

The historical data trend for Align Technology's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Align Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.07 77.55 22.52 10.01 12.31

Align Technology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.58 9.92 12.57 13.06 13.35

Competitive Comparison

For the Medical Devices subindustry, Align Technology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Align Technology ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's ROE % distribution charts can be found below:

* The bar in red indicates where Align Technology's ROE % falls into.



Align Technology ROE % Calculation

Align Technology's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=445.053/( (3601.358+3630.489)/ 2 )
=445.053/3615.9235
=12.31 %

Align Technology's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=496.056/( (3801.866+3630.489)/ 2 )
=496.056/3716.1775
=13.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Align Technology  (NAS:ALGN) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=496.056/3716.1775
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(496.056 / 3826.904)*(3826.904 / 6201.214)*(6201.214 / 3716.1775)
=Net Margin %*Asset Turnover*Equity Multiplier
=12.96 %*0.6171*1.6687
=ROA %*Equity Multiplier
=8 %*1.6687
=13.35 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=496.056/3716.1775
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (496.056 / 691.52) * (691.52 / 739.444) * (739.444 / 3826.904) * (3826.904 / 6201.214) * (6201.214 / 3716.1775)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7173 * 0.9352 * 19.32 % * 0.6171 * 1.6687
=13.35 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Align Technology ROE % Related Terms

Thank you for viewing the detailed overview of Align Technology's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Align Technology (Align Technology) Business Description

Traded in Other Exchanges
Address
410 North Scottsdale Road, Suite 1300, Tempe, AZ, USA, 85281
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the FDA in 1998, and it has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans and iTero scans make up over half of these scans.
Executives
Joseph M Hogan director, officer: President and CEO C/O ALIGN TECHNOLOGY, INC., 410 NORTH SCOTTSDALE ROAD, SUITE 1300, TEMPE AZ 85281
Kevin J Dallas director C/O ALIGN TECHNOLOGY INC., 2560 ORCHARD PARKWAY, SAN JOSE CA 95134
John Morici officer: Chief Financial Officer C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Anne Myong director 2820 ORCHARD PARKWAY, SAN JOSE CA 95141
Warren S Thaler director C/O ALIGN TECHNOLOGY, INC., 410 NORTH SCOTTSDALE ROAD, SUITE 1300, TEMPE AZ 85281
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105
Julie Ann Coletti officer: SVP, Chief Legal & Regulatory 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Greg J Santora director 4201 GRANT COURT, PLEASANTON CA 94566
Stuart A Hockridge officer: VP, Global Human Resources C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Emory Wright officer: VP, Operations C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
George J Morrow director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Andrea Lynn Saia director C/O COCA-COLA ENTERPRISES, INC., 2500 WINDY RIDGE PARKWAY, NW, 14TH FLOOR, ATLANTA GA 30339
Thomas M Prescott director C/O ALIGN TECHNOLOGY INC, 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Yuval Shaked officer: SVP and Mgng Director, Itero C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 95134
Jennifer Olson officer: VP& Mng Dir. D-DCC C/O ALIGN TECHNOLOGY, INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131

Align Technology (Align Technology) Headlines